SynthesisJournal of translational medicine2026
Biological tissue engineering for Fontan failure using decellularized extracellular matrix: a systematic review.
Synthesis in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional univentricular heart disease is the most severe congenital condition, managed by Fontan surgery, which is life-sustaining by creating a non-contractile conduit yet limited by long-term complications. Decellularized ECM (dECM) scaffolds reseeded with contractile human cells offer a promising solution, but key factors for such a biological tube remain undefined.
aimTo evaluate the potential of cardiac dECM as a scaffold for recellularization in the development of a contractile Fontan conduit.
methodsA systematic review was performed of studies identified in PubMed, Embase, Web of Science, and the Cochrane Library on human or porcine cardiac tissue engineering. Decellularization outcome parameters included efficiency of DNA removal, ECM preservation, and cytocompatibility; recellularization parameters focused on cell viability, co-culture strategies, maturation, and contractility.
resultsFifty-eight studies on decellularization of porcine or human cardiac tissue were included; 13 also investigated recellularization. Most studies reported more than 90% reduced DNA content and preserved ECM architecture, though quantitative ECM analyses and toxicity assessments were not often reported. Recellularization with cardiomyocyte (like) cells showed high viability, especially in slice monocultures. Co-culture with other cell types improved organization and sarcomere maturation. Functionality assessment in most studies showed spontaneous and synchronized contractions however remaining under normal physiological values.
conclusionCardiac dECM scaffolds hold promise for contractile Fontan conduits; however, standardized decellularization protocols, enhanced recellularization strategies, and integration of vascular and supportive cells are needed to advance clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.